Pritor

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
10-12-2020
产品特点 产品特点 (SPC)
10-12-2020
公众评估报告 公众评估报告 (PAR)
05-11-2015

有效成分:

Telmisartan

可用日期:

Bayer AG

ATC代码:

C09CA07

INN(国际名称):

telmisartan

治疗组:

Agents acting on the renin-angiotensin system

治疗领域:

Hypertension

疗效迹象:

HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

產品總結:

Revision: 29

授权状态:

Authorised

授权日期:

1998-12-11

资料单张

                                35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRITOR 20 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pritor is and what it is used for
2.
What you need to know before you take Pritor
3.
How to take Pritor
4.
Possible side effects
5.
How to store Pritor
6.
Contents of the pack and other information
1.
WHAT PRITOR IS AND WHAT IT IS USED FOR
Pritor belongs to a class of medicines known as angiotensin II
receptor antagonists. Angiotensin II is a
substance produced in your body which causes your blood vessels to
narrow, thus increasing your
blood pressure. Pritor blocks the effect of angiotensin II so that the
blood vessels relax, and your
blood pressure is lowered.
PRITOR IS USED TO treat essential hypertension (high blood pressure)
in adults. ‘Essential’ means that
the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
PRITOR IS ALSO USED TO reduce cardiovascular events (i.e. heart attack
or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, or have had a stroke or
have high risk diabetes. Your doctor can tell you if you are at high
risk for suc
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pritor 20 mg tablets
Pritor 40 mg tablets
Pritor 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pritor 20 mg tablets
Each tablet contains 20 mg telmisartan.
Pritor 40 mg tablets
Each tablet contains 40 mg telmisartan.
Pritor 80 mg tablets
Each tablet contains 80 mg telmisartan.
Excipients with known effect
Each 20 mg tablet contains 84 mg sorbitol (E420).
Each 40 mg tablet contains 169 mg sorbitol (E420).
Each 80 mg tablet contains 338 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pritor 20 mg tablets
White round tablets of 2.5 mm engraved with the code number '50H' on
one side and the company
logo on the other side.
Pritor 40 mg tablets
White oblong tablets of 3.8 mm engraved with the code number '51H' on
one side.
Pritor 80 mg tablets
White oblong tablets of 4.6 mm engraved with the code number '52H' on
one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:

manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or
peripheral arterial disease) or

type 2 diabetes mellitus with documented target organ damage
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Treatment of essential hypertension_
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of
20 mg. In cases where the target blood pressure is not achieved, the
dose of telmisartan can be
increased to a maximum of 80 mg once daily. Alternatively, telmisartan
may be used in combination
with thiazide-type diuretics such as hydrochlorothiazide, which has
been shown to have an additive
blood pressure lowering effect with telmisartan. When considering
raising the dose, it must be borne
in mind that the maximum antihypertensive effect is generally attained
four to eight weeks after the

                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 10-12-2020
产品特点 产品特点 保加利亚文 10-12-2020
公众评估报告 公众评估报告 保加利亚文 05-11-2015
资料单张 资料单张 西班牙文 10-12-2020
产品特点 产品特点 西班牙文 10-12-2020
公众评估报告 公众评估报告 西班牙文 05-11-2015
资料单张 资料单张 捷克文 10-12-2020
产品特点 产品特点 捷克文 10-12-2020
公众评估报告 公众评估报告 捷克文 05-11-2015
资料单张 资料单张 丹麦文 10-12-2020
产品特点 产品特点 丹麦文 10-12-2020
公众评估报告 公众评估报告 丹麦文 05-11-2015
资料单张 资料单张 德文 10-12-2020
产品特点 产品特点 德文 10-12-2020
公众评估报告 公众评估报告 德文 05-11-2015
资料单张 资料单张 爱沙尼亚文 10-12-2020
产品特点 产品特点 爱沙尼亚文 10-12-2020
公众评估报告 公众评估报告 爱沙尼亚文 05-11-2015
资料单张 资料单张 希腊文 10-12-2020
产品特点 产品特点 希腊文 10-12-2020
公众评估报告 公众评估报告 希腊文 05-11-2015
资料单张 资料单张 法文 10-12-2020
产品特点 产品特点 法文 10-12-2020
公众评估报告 公众评估报告 法文 05-11-2015
资料单张 资料单张 意大利文 10-12-2020
产品特点 产品特点 意大利文 10-12-2020
公众评估报告 公众评估报告 意大利文 05-11-2015
资料单张 资料单张 拉脱维亚文 10-12-2020
产品特点 产品特点 拉脱维亚文 10-12-2020
公众评估报告 公众评估报告 拉脱维亚文 05-11-2015
资料单张 资料单张 立陶宛文 10-12-2020
产品特点 产品特点 立陶宛文 10-12-2020
公众评估报告 公众评估报告 立陶宛文 05-11-2015
资料单张 资料单张 匈牙利文 10-12-2020
产品特点 产品特点 匈牙利文 10-12-2020
公众评估报告 公众评估报告 匈牙利文 05-11-2015
资料单张 资料单张 马耳他文 10-12-2020
产品特点 产品特点 马耳他文 10-12-2020
公众评估报告 公众评估报告 马耳他文 05-11-2015
资料单张 资料单张 荷兰文 10-12-2020
产品特点 产品特点 荷兰文 10-12-2020
公众评估报告 公众评估报告 荷兰文 05-11-2015
资料单张 资料单张 波兰文 10-12-2020
产品特点 产品特点 波兰文 10-12-2020
公众评估报告 公众评估报告 波兰文 05-11-2015
资料单张 资料单张 葡萄牙文 10-12-2020
产品特点 产品特点 葡萄牙文 10-12-2020
公众评估报告 公众评估报告 葡萄牙文 05-11-2015
资料单张 资料单张 罗马尼亚文 10-12-2020
产品特点 产品特点 罗马尼亚文 10-12-2020
公众评估报告 公众评估报告 罗马尼亚文 05-11-2015
资料单张 资料单张 斯洛伐克文 10-12-2020
产品特点 产品特点 斯洛伐克文 10-12-2020
公众评估报告 公众评估报告 斯洛伐克文 05-11-2015
资料单张 资料单张 斯洛文尼亚文 10-12-2020
产品特点 产品特点 斯洛文尼亚文 10-12-2020
公众评估报告 公众评估报告 斯洛文尼亚文 05-11-2015
资料单张 资料单张 芬兰文 10-12-2020
产品特点 产品特点 芬兰文 10-12-2020
公众评估报告 公众评估报告 芬兰文 05-11-2015
资料单张 资料单张 瑞典文 10-12-2020
产品特点 产品特点 瑞典文 10-12-2020
公众评估报告 公众评估报告 瑞典文 05-11-2015
资料单张 资料单张 挪威文 10-12-2020
产品特点 产品特点 挪威文 10-12-2020
资料单张 资料单张 冰岛文 10-12-2020
产品特点 产品特点 冰岛文 10-12-2020
资料单张 资料单张 克罗地亚文 10-12-2020
产品特点 产品特点 克罗地亚文 10-12-2020
公众评估报告 公众评估报告 克罗地亚文 05-11-2015

搜索与此产品相关的警报

查看文件历史